{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:59:29Z","timestamp":1790891969899,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["Local project"],"award-info":[{"award-number":["Local project"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>5q-Associated spinal muscular atrophy is a hereditary neuromuscular disease leading to progressive muscle weakness in which fatigue occurs and affects quality of life. Treatment with the antisense oligonucleotide nusinersen has been shown to improve motor function. Fatigue can be measured within the Fatigue Severity Scale (FSS). FSS is a self-reported questionnaire consisting of nine items to quantify fatigue severity within the last week. Higher values indicating a higher severity. Using the FSS, fatigue was measured in 28 adult patients, subdivided into ambulatory and non-ambulatory, suffering from a genetically confirmed 5q-SMA under treatment with nusinersen in accordance with the label. Correlations were performed among FSS and motor scales, 6-minute walk test (6MWT) and Hammersmiths Functional Motor Scale Expanded (HFMSE). Evaluation was performed prior to treatment initiation and after 6 and 10\u00a0months. The mean FSS score for all 28 patients at baseline was 4.61\u2009\u00b1\u20091.44. After 6\u00a0months mean FSS score significantly reduced to 3.92\u2009\u00b1\u20091.35. After 10\u00a0months mean FSS score had not differed from baseline, 3.84\u2009\u00b1\u20091.25. A moderate negative correlation of the difference of FSS and 6MWT after 6\u00a0months compared to baseline conditions was measured. Nusinersen reduces fatigue as measured by the FSS in adult patients with 5q-SMA transiently after initiation of treatment. There was no reduction of FSS 10\u00a0months after the beginning of treatment when compared to baseline.<\/jats:p>","DOI":"10.1038\/s41598-020-68051-w","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T10:03:14Z","timestamp":1594029794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Fatigue in adults with spinal muscular atrophy under treatment with nusinersen"],"prefix":"10.1038","volume":"10","author":[{"given":"K.","family":"Kizina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Stolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Totzeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"von Velsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"68051_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265\u2013269. https:\/\/doi.org\/10.1038\/ng0797-265 (1997).","journal-title":"Nat. Genet."},{"key":"68051_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155\u2013165 (1995).","journal-title":"Cell"},{"key":"68051_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri, E., Bertini, E. & Iannaccone, S. T. Childhood spinal muscular atrophy: Controversies and challenges. Lancet Neurol. 11, 443\u2013452. https:\/\/doi.org\/10.1016\/S1474-4422(12)70061-3 (2012).","journal-title":"Lancet Neurol."},{"key":"68051_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnana.2016.00006","volume":"10","author":"M Boido","year":"2016","unstructured":"Boido, M. & Vercelli, A. Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy. Front. Neuroanat. 10, 6. https:\/\/doi.org\/10.3389\/fnana.2016.00006 (2016).","journal-title":"Front. Neuroanat."},{"key":"68051_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres, K. et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J. Neurol. Sci. 146, 67\u201372 (1997).","journal-title":"J. Neurol. Sci."},{"key":"68051_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","volume":"2","author":"TL Munsat","year":"1992","unstructured":"Munsat, T. L. & Davies, K. E. International SMA consortium meeting. (26\u201328 June 1992, Bonn, Germany). Neuromuscul. Disord. 2, 423\u2013428 (1992).","journal-title":"Neuromuscul. Disord."},{"key":"68051_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D'Amico","year":"2011","unstructured":"D\u2019Amico, A., Mercuri, E., Tiziano, F. D. & Bertini, E. Spinal muscular atrophy. Orphanet. J. Rare Dis. 6, 71. https:\/\/doi.org\/10.1186\/1750-1172-6-71 (2011).","journal-title":"Orphanet. J. Rare Dis."},{"key":"68051_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.pmrj.2010.04.003","volume":"2","author":"H Landmark-Hoyvik","year":"2010","unstructured":"Landmark-Hoyvik, H. et al. The genetics and epigenetics of fatigue. PMR 2, 456\u2013465. https:\/\/doi.org\/10.1016\/j.pmrj.2010.04.003 (2010).","journal-title":"PMR"},{"key":"68051_CR9","first-page":"164","volume":"8","author":"MP Davis","year":"2010","unstructured":"Davis, M. P. & Walsh, D. Mechanisms of fatigue. J. Support. Oncol. 8, 164\u2013174 (2010).","journal-title":"J. Support. Oncol."},{"key":"68051_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0140-6736(04)15794-2","volume":"363","author":"A Chaudhuri","year":"2004","unstructured":"Chaudhuri, A. & Behan, P. O. Fatigue in neurological disorders. Lancet 363, 978\u2013988. https:\/\/doi.org\/10.1016\/S0140-6736(04)15794-2 (2004).","journal-title":"Lancet"},{"issue":"Suppl 3","key":"68051_CR11","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1016\/j.nmd.2012.10.010","volume":"22","author":"C Angelini","year":"2012","unstructured":"Angelini, C. & Tasca, E. Fatigue in muscular dystrophies. Neuromuscul. Disord. 22(Suppl 3), S214-220. https:\/\/doi.org\/10.1016\/j.nmd.2012.10.010 (2012).","journal-title":"Neuromuscul. Disord."},{"key":"68051_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/03009740801914868","volume":"37","author":"M Mattsson","year":"2008","unstructured":"Mattsson, M., Moller, B., Lundberg, I., Gard, G. & Bostrom, C. Reliability and validity of the Fatigue Severity Scale in Swedish for patients with systemic lupus erythematosus. Scand. J. Rheumatol. 37, 269\u2013277. https:\/\/doi.org\/10.1080\/03009740801914868 (2008).","journal-title":"Scand. J. Rheumatol."},{"key":"68051_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1023\/A:1008960710415","volume":"9","author":"L Kleinman","year":"2000","unstructured":"Kleinman, L. et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual. Life Res. 9, 499\u2013508 (2000).","journal-title":"Qual. Life Res."},{"issue":"Suppl 11","key":"68051_CR14","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1002\/acr.20579","volume":"63","author":"S Hewlett","year":"2011","unstructured":"Hewlett, S., Dures, E. & Almeida, C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res. (Hoboken) 63(Suppl 11), S263-286. https:\/\/doi.org\/10.1002\/acr.20579 (2011).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"68051_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1468-1331.2002.00444.x","volume":"9","author":"K Herlofson","year":"2002","unstructured":"Herlofson, K. & Larsen, J. P. Measuring fatigue in patients with Parkinson\u2019s disease\u2014the Fatigue Severity Scale. Eur. J. Neurol. 9, 595\u2013600 (2002).","journal-title":"Eur. J. Neurol."},{"key":"68051_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1177\/0883073815627879","volume":"31","author":"Y Wei","year":"2016","unstructured":"Wei, Y., Speechley, K. N., Zou, G. & Campbell, C. Factors associated with health-related quality of life in children with duchenne muscular dystrophy. J. Child Neurol. 31, 879\u2013886. https:\/\/doi.org\/10.1177\/0883073815627879 (2016).","journal-title":"J. Child Neurol."},{"key":"68051_CR17","doi-asserted-by":"crossref","unstructured":"European Medicines Agency (EMA). (2017).","DOI":"10.26226\/morressier.57d034d4d462b80292383e46"},{"key":"68051_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/jpet.113.212407","volume":"350","author":"F Rigo","year":"2014","unstructured":"Rigo, F. et al. Pharmacology of a central nervous system delivered 2\u2019-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46\u201355. https:\/\/doi.org\/10.1124\/jpet.113.212407 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"68051_CR19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752 (2017).","journal-title":"N. Engl. J. Med."},{"key":"68051_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378, 625\u2013635. https:\/\/doi.org\/10.1056\/NEJMoa1710504 (2018).","journal-title":"N. Engl. J. Med."},{"key":"68051_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.26633","volume":"60","author":"J Montes","year":"2019","unstructured":"Montes, J. et al. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve 60, 409\u2013414. https:\/\/doi.org\/10.1002\/mus.26633 (2019).","journal-title":"Muscle Nerve"},{"key":"68051_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","volume":"74","author":"J Montes","year":"2010","unstructured":"Montes, J. et al. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74, 833\u2013838. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d3e308 (2010).","journal-title":"Neurology"},{"key":"68051_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp, L. B., LaRocca, N. G., Muir-Nash, J. & Steinberg, A. D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 46, 1121\u20131123. https:\/\/doi.org\/10.1001\/archneur.1989.00520460115022 (1989).","journal-title":"Arch. Neurol."},{"key":"68051_CR24","unstructured":"24AbilityLab, S. R. Fatigue Severity Scale. https:\/\/www.sralab.org\/rehabilitation-measures\/fatigue-severity-scale (2016)."},{"key":"68051_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young, S. et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 54, 836\u2013842. https:\/\/doi.org\/10.1002\/mus.25120 (2016).","journal-title":"Muscle Nerve"},{"key":"68051_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera, M. C. et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 17, 39. https:\/\/doi.org\/10.1186\/s12883-017-0790-9 (2017).","journal-title":"BMC Neurol."},{"key":"68051_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker, T. et al. Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study. Lancet Neurol. 19, 317\u2013325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30037-5 (2020).","journal-title":"Lancet Neurol."},{"key":"68051_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter, M. C. et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA Type 3: A prospective observational study. J. Neuromuscul. Dis. 6, 453\u2013465. https:\/\/doi.org\/10.3233\/JND-190416 (2019).","journal-title":"J. Neuromuscul. Dis."},{"key":"68051_CR29","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.clinph.2012.12.053","volume":"124","author":"Y Noto","year":"2013","unstructured":"Noto, Y. et al. Prominent fatigue in spinal muscular atrophy and spinal and bulbar muscular atrophy: Evidence of activity-dependent conduction block. Clin. Neurophysiol. 124, 1893\u20131898. https:\/\/doi.org\/10.1016\/j.clinph.2012.12.053 (2013).","journal-title":"Clin. Neurophysiol."},{"key":"68051_CR30","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s11136-013-0565-8","volume":"23","author":"U Werlauff","year":"2014","unstructured":"Werlauff, U., Hojberg, A., Firla-Holme, R., Steffensen, B. F. & Vissing, J. Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: Evaluation of the fatigue severity scale. Qual. Life Res. 23, 1479\u20131488. https:\/\/doi.org\/10.1007\/s11136-013-0565-8 (2014).","journal-title":"Qual. Life Res."},{"key":"68051_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14034940410028406","volume":"33","author":"A Lerdal","year":"2005","unstructured":"Lerdal, A., Wahl, A., Rustoen, T., Hanestad, B. R. & Moum, T. Fatigue in the general population: A translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand. J. Public Health 33, 123\u2013130. https:\/\/doi.org\/10.1080\/14034940410028406 (2005).","journal-title":"Scand. J. Public Health"},{"key":"68051_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14248","author":"B El-Aloul","year":"2019","unstructured":"El-Aloul, B., Speechley, K. N., Wei, Y., Wilk, P. & Campbell, C. Fatigue in young people with Duchenne muscular dystrophy. Dev. Med. Child Neurol. https:\/\/doi.org\/10.1111\/dmcn.14248 (2019).","journal-title":"Dev. Med. Child Neurol."},{"key":"68051_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1191\/1352458502ms839oa","volume":"8","author":"P Flachenecker","year":"2002","unstructured":"Flachenecker, P. et al. Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical parameters. Mult. Scler. 8, 523\u2013526. https:\/\/doi.org\/10.1191\/1352458502ms839oa (2002).","journal-title":"Mult. Scler."},{"key":"68051_CR34","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/sleep\/31.11.1601","volume":"31","author":"PO Valko","year":"2008","unstructured":"Valko, P. O., Bassetti, C. L., Bloch, K. E., Held, U. & Baumann, C. R. Validation of the fatigue severity scale in a Swiss cohort. Sleep 31, 1601\u20131607. https:\/\/doi.org\/10.1093\/sleep\/31.11.1601 (2008).","journal-title":"Sleep"},{"key":"68051_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-180342","volume":"6","author":"S Dunaway Young","year":"2019","unstructured":"Dunaway Young, S. et al. Perceived fatigue in spinal muscular atrophy: A pilot study. J. Neuromuscul. Dis. 6, 109\u2013117. https:\/\/doi.org\/10.3233\/JND-180342 (2019).","journal-title":"J. Neuromuscul. Dis."},{"key":"68051_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1891\/1061-3749.26.1.36","volume":"26","author":"B Belza","year":"2018","unstructured":"Belza, B. et al. A systematic review of studies using the multidimensional assessment of fatigue scale. J. Nurs. Meas. 26, 36\u201375. https:\/\/doi.org\/10.1891\/1061-3749.26.1.36 (2018).","journal-title":"J. Nurs. Meas."},{"issue":"Suppl 1","key":"68051_CR37","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/clinids\/18.supplement_1.s79","volume":"18","author":"JD Fisk","year":"1994","unstructured":"Fisk, J. D. et al. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clin. Infect. Dis. 18(Suppl 1), S79-83. https:\/\/doi.org\/10.1093\/clinids\/18.supplement_1.s79 (1994).","journal-title":"Clin. Infect. Dis."},{"key":"68051_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12883-019-1244-3","volume":"19","author":"B Bartels","year":"2019","unstructured":"Bartels, B. et al. Assessment of fatigability in patients with spinal muscular atrophy: Development and content validity of a set of endurance tests. BMC Neurol. 19, 21. https:\/\/doi.org\/10.1186\/s12883-019-1244-3 (2019).","journal-title":"BMC Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68051-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68051-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68051-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:32:58Z","timestamp":1670333578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68051-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["68051"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-68051-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.K. received travel reimbursement from Biogen. B.S. and C.K. received travel reimbursement and speaker honoraria from Biogen. T.H. received travel reimbursement from Biogen and speaker honoraria from Novartis and Biogen and research support from Biogen. S.B., M. S., A.T., C.O. and O.V V declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11069"}}